Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies (Q37802195)

23 August 2017

title

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies (English)

1 reference

23 August 2017

6

P Hainaut

1 reference

23 August 2017

I Goldstein

1

1 reference

23 August 2017

V Marcel

2

1 reference

23 August 2017

M Olivier

3

1 reference

23 August 2017

M Oren

4

1 reference

23 August 2017

V Rotter

5

1 reference

23 August 2017

publication date

22 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

18

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

2-11

1 reference

Definition of a consensus binding site for p53

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Structural basis of DNA recognition by p53 tetramers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Noncanonical DNA motifs as transactivation targets by wild type and mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

A regulatory loop composed of RAP80-HDM2-p53 provides RAP80-enhanced p53 degradation by HDM2 in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

21 January 2018

Modes of p53 regulation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Identification of new p53 acetylation sites in COS-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

An oncogene-induced DNA damage model for cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

MdmX regulates transformation and chromosomal stability in p53-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

21 January 2018

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Cancer cells suppress p53 in adjacent fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Id proteins at the cross-road of development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Nuclear bodies and compartments: functional roles and cellular signalling in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Identification of a tumour suppressor network opposing nuclear Akt function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Loss of the tumor suppressor PML in human cancers of multiple histologic origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Promyelocytic leukemia protein is required for gain of function by mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Recent advances in p53 research: an interdisciplinary perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

CDK9 phosphorylates p53 on serine residues 33, 315 and 392

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

Regulation of apoptosis and differentiation by p53 in human embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

When mutants gain new powers: news from the mutant p53 field.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.63

7 January 2021

Identifiers

DOI

10.1038/CGT.2010.63

1 reference

Dimensions Publication ID

23 August 2017

1017643191

0 references

1 reference